ASCO-GI-Webinar-Update-on-NET-and-HCC_Ipsen-1

ASCO GI Webinar: Update on NET and HCC

There is no excerpt because this is a protected post.

ASCO-2021-Liver-Cancer-Update

ASCO 2021 Liver Cancer Update

The liver cancer trials presented at American Society of Clinical Oncology (ASCO) 2021 were mainly focused on first-line treatments, with a few trials in the neoadjuvant, adjuvant and second-line setting.

Effect-of-prior-therapy-on-BRAF-V600E-mutant-metastatic-colorectal-cancer

Effect of prior therapy on BRAF V600E-mutant metastatic colorectal cancer

An exploratory post-hoc analysis of the BEACON CRC study investigated the overall survival (OS) of encorafenib + cetuximab (doublet) and FOLFIRI (control) according to prior therapies (bevacizumab, oxaliplatin, FOLFOXIRI and anticancer therapy [ACT]) in BRAF V600E-mutant metastatic colorectal cancer (mCRC).

cabotegravir-and-rilpivirine-intramuscular-combination-safe-in-women

Cabotegravir and rilpivirine intramuscular combination safe in women

Women account for a disproportionate percentage of new human immunodeficiency virus (HIV) infections in sub-Saharan Africa, comprising 59% of 18 million new adult HIV infections in 2017.

hcv-infected-kidneys-safe-for-transplantation-with-antiviral-treatment

HCV-infected kidneys safe for transplantation with antiviral treatment

Kidney transplants are the best treatment for end-stage renal disease (ESRD), with better survival outcomes than haemodialysis or peritoneal dialysis. However, in Hong Kong as well as much of the rest of the world, there is an increasing gap between the number of patients requiring a transplant and the number of organs available.

baloxavir-marboxil-recommended-as-post-exposure-prophylaxis-to-influenza-by-ema

Baloxavir marboxil recommended as post-exposure prophylaxis to influenza by EMA

Seasonal influenza is common between January to March, and July to August in Hong Kong. Baloxavir marboxil is the first influenza antiviral with a novel mechanism of action to be approved in almost two decades, and was registered for use in Hong Kong in February 2019.

U.S.-FDA-approved-immunecheckpoint-inhibitors-e1528902398517

US FDA approved immune-checkpoint inhibitors updated 08-Dec-2020

Know all the United States Food and Drug Administration (U.S. FDA) approved immune-checkpoint inhibitors. Members of MediPaper can download the free PPT slides summarising the U.S. FDA approved immune-checkpoint inhibitors and other U.S. FDA approved immunotherapies.

asco-guidelines-for-the-use-of-systemic-therapies-in-advanced-hepatocellular-cancer

ASCO Guidelines for the Use of Systemic Therapies in Advanced Hepatocellular Cancer

Hepatocellular carcinoma (HCC) accounts for 80% of all liver cancers, and 55% of all HCC cases worldwide are reported from China. In Hong Kong, liver cancer is the fourth most common cancer and the third most common cause of cancer death.

Sotorasib-for-the-treatment-of-KRASG12C-mutated-lung-cancer

Sotorasib for the treatment of KRASG12C mutated lung cancer

RAS is the most frequently mutated gene family in cancers, with KRAS mutations being involved as a driver in three of the most lethal cancers – lung cancer, colorectal cancer, and pancreatic cancer. Incidence of KRAS mutations vary between ethnicity with Caucasians having a higher incidence than African-Americans or Asians. In non-small lung cancer (NSCLC), the most common KRAS mutation is G12C. In Asia, G12C mutations in particular account for 14.5% of KRAS mutations in the Chinese population. KRAS G12C was identified in 4.3% of lung cancer samples and 2.5% of colorectal cancer samples.

First-liquid-biopsy-for-NSCLC-to-receive-FDA-approval

First liquid biopsy for NSCLC to receive FDA approval

The development of new targeted therapies for non-small cell lung cancer (NSCLC) in recent years has changed the standard of care for the later stages of NSCLC in specific population groups.